Payers: Lynparza Coverage Will Be at Parity With Other Second-Line Prostate Cancer Drugs
August 1
AstraZeneca and Merck & Co., Inc. released positive results of Lynparza’s Phase III PROfound trial last August. Shortly thereafter, from Sept. 3, 2019, to Oct. 7, 2019, Zitter Insights polled 51 commercial payers with 158.4 million covered lives about how they were likely to manage the therapy.
Commercial payers with 60% of covered lives said they were more likely than unlikely and significantly likely to manage Lynparza at parity with other drugs in the second-line treatment of metastatic castration- resistant prostate cancer (see chart below). The same percentage of payers said they were neither likely nor unlikely to cover it over all other therapies.
Related Posts
May 11
Study Finds Fertility Program Prevents Medication Waste, Loss, Missed Doses
READ MORE
May 11
New FDA Approvals: FDA Expands Patient Population of Takeda’s HyQvia
READ MORE
May 11
AbbVie Files Lawsuit Against Alternate Funding Company Payer Matrix Alleging ‘Fraudulent and Deceptive Scheme’
READ MORE
Meet Our Reporters
-
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Peter Johnson Reporter, Health Plan Weekly and Radar on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile
